Authors

BCG-unresponsive NMIBC: Current evidence and options

Multiple investigational agents have been developed and are being studied.

Malpractice Consult: What to know about closing arguments

"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.

Financial toxicity is a growing concern in urologic oncology

"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.

Management of BCG-unresponsive NMIBC

"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.

Upper tract urothelial carcinoma: An in-depth review for urologists

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.

Study shows HIFU noninferior to prostatectomy for localized prostate cancer

Treating patients with localized prostate cancer with high-intensity focused ultrasound led to noninferior salvage treatment-free survival vs radical prostatectomy.

Biomarker may predict MIBC status following neoadjuvant chemo

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.

Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer Care

The conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.

How to perform office-based blue light cystoscopy

BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.

Trends in coding audits and what physicians can expect

Recent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.

Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC

Ultimately, the take-home message for practicing urologists is to apply TMT judiciously, taking into account the patient's clinical profile, personal values, and financial situation.

Smaller medical practices increasingly targeted for cyber attacks

Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.

Expert shares key cybersecurity fundamentals and best practices

Cybersecurity training is vital because it is mandated by HIPAA.

Phase 3 CELLEBRATE trial testing regenerative stem cell-based therapy to improve urinary control for women

The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

Expert urges widespread adoption of next-generation sequencing among physicians

NGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.

UT Money Matters: Roth IRA conversions

Expert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.

How to approach immune checkpoint inhibitor therapy in prostate cancer

Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.

Discover the Art and Science Behind Nerve Sparing Prostate Surgery

In his latest YouTube masterclass, Dr. Ash Tewari shares his groundbreaking approach to nerve sparing prostate surgery, shedding light on the anatomy, surgical techniques, and innovations that make it possible.

Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New Frontier

Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Diversity in Urology: Progress made, but there is more work to be done

Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.

What steps can physicians take to overcome barriers to health equity?

“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.

177Lu-PSMA-617 prolongs rPFS in taxane-naïve mCRPC, benefit greater with prior abiraterone vs enzalutamide

Lutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.

Practical guide to female pelvic organ–sparing radical cystectomy

Early Recurrent Low-Grade, Intermediate-Risk NMIBC

Panelists discuss how patients with early recurrent low-grade bladder cancer, especially those on an anticoagulant or with multiple risk factors, represent ideal candidates for ablative therapy with UGN-102 to break the cycle of repeated transurethral resection of bladder tumors (TURBTs) and provide a paradigm shift from purely surgical management to shared decision-making between surgical and medical treatment options.

Balancing the benefits and risks of AI in health care

“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.